Immunization of AGE-modified albumin inhibits diabetic nephropathy progression in diabetic mice

Musthika Wida Mashitah,1 Nurona Azizah,1 Nur Samsu,2 Muhammad Rasjad Indra,1 Muhammad Bilal,3 Meti Verdian Yunisa,4 Amildya Dwi Arisanti41Department of Biomedicine, Faculty of Medicine, Brawijaya University, Malang, 2Department of Internal Medicine, Division of Nephrology and Hypertension, Saiful An...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mashitah MW, Azizah N, Samsu N, Indra MR, Bilal M, Yunisa MV, Arisanti AD
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/d4199c929e77490ab6c8eae3b0235804
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d4199c929e77490ab6c8eae3b0235804
record_format	dspace
spelling	oai:doaj.org-article:d4199c929e77490ab6c8eae3b02358042021-12-02T04:58:48ZImmunization of AGE-modified albumin inhibits diabetic nephropathy progression in diabetic mice1178-7007https://doaj.org/article/d4199c929e77490ab6c8eae3b02358042015-08-01T00:00:00Zhttp://www.dovepress.com/immunization-of-age-modified-albumin-inhibits-diabetic-nephropathy-pro-peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007Musthika Wida Mashitah,1 Nurona Azizah,1 Nur Samsu,2 Muhammad Rasjad Indra,1 Muhammad Bilal,3 Meti Verdian Yunisa,4 Amildya Dwi Arisanti41Department of Biomedicine, Faculty of Medicine, Brawijaya University, Malang, 2Department of Internal Medicine, Division of Nephrology and Hypertension, Saiful Anwar General Hospital, Malang, 3Department of Medicine, Faculty of Medicine, Brawijaya University, Malang, 4Department of Nursing, Faculty of Medicine, Brawijaya University, Malang, IndonesiaBackground: Diabetic nephropathy (DN) is a serious vascular complication of diabetes and an important cause of end-stage renal disease. One mechanism by which hyperglycemia causes nephropathy is through the formation of advanced glycation end products (AGE). Development of vaccination would be a promising therapy for the future, while to date, anti-AGE therapy is based on medicines that are needed to be consumed lifelong. This study aimed to find out the effect of immunization of AGE-modified albumin against DN pathogenesis in streptozotocin-induced diabetic in mice.Methods: We used 24 BALB/c male mice as experimental animals, which were divided into six groups, two nondiabetic groups (negative control and AGE-modified bovine serum albumin [BSA] preimmunized groups) and four streptozotocin-induced diabetic groups (diabetic control group and diabetic preimmunized groups for AGE-BSA, Keyhole limpet hemocyanin (KLH), and AGE-BSA-KLH, respectively).Results: Diabetic preimmunized groups for AGE-BSA, KLH, and AGE-BSA-KLH showed amelioration in renal function and histopathology compared with the diabetic control group. Preimmunization also maintained nephrin intensity and decreased serum AGE level, kidney AGE deposition, and kidney cells apoptosis.Conclusion: AGE-BSA and AGE-BSA-KLH immunizations inhibit the progression of DN. Our results strengthen the evidence that the anti-AGE antibodies have a protective role against diabetic vascular complication, especially DN. This study provides a basis for the development of DN-based immunotherapy with AGE immunization as a potential candidate.Keywords: immunization, advanced glycation end products (AGE), AGE-modified albumin, anti-AGE antibody, diabetic nephropathyMashitah MWAzizah NSamsu NIndra MRBilal MYunisa MVArisanti ADDove Medical PressarticleSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol 2015, Iss default, Pp 347-355 (2015)
institution	DOAJ
collection	DOAJ
language	EN
topic	Specialties of internal medicine RC581-951
spellingShingle	Specialties of internal medicine RC581-951 Mashitah MW Azizah N Samsu N Indra MR Bilal M Yunisa MV Arisanti AD Immunization of AGE-modified albumin inhibits diabetic nephropathy progression in diabetic mice
description	Musthika Wida Mashitah,1 Nurona Azizah,1 Nur Samsu,2 Muhammad Rasjad Indra,1 Muhammad Bilal,3 Meti Verdian Yunisa,4 Amildya Dwi Arisanti41Department of Biomedicine, Faculty of Medicine, Brawijaya University, Malang, 2Department of Internal Medicine, Division of Nephrology and Hypertension, Saiful Anwar General Hospital, Malang, 3Department of Medicine, Faculty of Medicine, Brawijaya University, Malang, 4Department of Nursing, Faculty of Medicine, Brawijaya University, Malang, IndonesiaBackground: Diabetic nephropathy (DN) is a serious vascular complication of diabetes and an important cause of end-stage renal disease. One mechanism by which hyperglycemia causes nephropathy is through the formation of advanced glycation end products (AGE). Development of vaccination would be a promising therapy for the future, while to date, anti-AGE therapy is based on medicines that are needed to be consumed lifelong. This study aimed to find out the effect of immunization of AGE-modified albumin against DN pathogenesis in streptozotocin-induced diabetic in mice.Methods: We used 24 BALB/c male mice as experimental animals, which were divided into six groups, two nondiabetic groups (negative control and AGE-modified bovine serum albumin [BSA] preimmunized groups) and four streptozotocin-induced diabetic groups (diabetic control group and diabetic preimmunized groups for AGE-BSA, Keyhole limpet hemocyanin (KLH), and AGE-BSA-KLH, respectively).Results: Diabetic preimmunized groups for AGE-BSA, KLH, and AGE-BSA-KLH showed amelioration in renal function and histopathology compared with the diabetic control group. Preimmunization also maintained nephrin intensity and decreased serum AGE level, kidney AGE deposition, and kidney cells apoptosis.Conclusion: AGE-BSA and AGE-BSA-KLH immunizations inhibit the progression of DN. Our results strengthen the evidence that the anti-AGE antibodies have a protective role against diabetic vascular complication, especially DN. This study provides a basis for the development of DN-based immunotherapy with AGE immunization as a potential candidate.Keywords: immunization, advanced glycation end products (AGE), AGE-modified albumin, anti-AGE antibody, diabetic nephropathy
format	article
author	Mashitah MW Azizah N Samsu N Indra MR Bilal M Yunisa MV Arisanti AD
author_facet	Mashitah MW Azizah N Samsu N Indra MR Bilal M Yunisa MV Arisanti AD
author_sort	Mashitah MW
title	Immunization of AGE-modified albumin inhibits diabetic nephropathy progression in diabetic mice
title_short	Immunization of AGE-modified albumin inhibits diabetic nephropathy progression in diabetic mice
title_full	Immunization of AGE-modified albumin inhibits diabetic nephropathy progression in diabetic mice
title_fullStr	Immunization of AGE-modified albumin inhibits diabetic nephropathy progression in diabetic mice
title_full_unstemmed	Immunization of AGE-modified albumin inhibits diabetic nephropathy progression in diabetic mice
title_sort	immunization of age-modified albumin inhibits diabetic nephropathy progression in diabetic mice
publisher	Dove Medical Press
publishDate	2015
url	https://doaj.org/article/d4199c929e77490ab6c8eae3b0235804
work_keys_str_mv	AT mashitahmw immunizationofagemodifiedalbumininhibitsdiabeticnephropathyprogressionindiabeticmice AT azizahn immunizationofagemodifiedalbumininhibitsdiabeticnephropathyprogressionindiabeticmice AT samsun immunizationofagemodifiedalbumininhibitsdiabeticnephropathyprogressionindiabeticmice AT indramr immunizationofagemodifiedalbumininhibitsdiabeticnephropathyprogressionindiabeticmice AT bilalm immunizationofagemodifiedalbumininhibitsdiabeticnephropathyprogressionindiabeticmice AT yunisamv immunizationofagemodifiedalbumininhibitsdiabeticnephropathyprogressionindiabeticmice AT arisantiad immunizationofagemodifiedalbumininhibitsdiabeticnephropathyprogressionindiabeticmice
_version_	1718400981315616768

Immunization of AGE-modified albumin inhibits diabetic nephropathy progression in diabetic mice

Ejemplares similares